Sequential trial with B method of Potvin [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2015-10-01 19:58 (3907 d 07:18 ago) – Posting: # 15514
Views: 14,214

Hi JJ,

❝ In a sequential clinical trial conducted like a B method of Potvin, we have Cmax and AUC both not bioequivalent. Cmax has a power <80% (71.5%), and AUC>80% (84.6%).

❝ AUC 0-30min calculated by protocol is bioequivalent.

❝ In the protocol it was not specified how to proceed in this situation.


❝ Can we calculate a new n and pass to the second phase? Or we must stop the trial?


I would go by the metric that displays the highest variance, which is usually Cmax. I suggest to proceed towards stage 2 on that basis.
However, since this was not pre-specified it is your protocol that document may be your biggest issue now; regulators may not like whatever decision you take.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
152 visitors (0 registered, 152 guests [including 41 identified bots]).
Forum time: 03:16 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5